L3Harris Technologies, Inc. (NYSE: LHX) — A Supercycle Growth Multiple Stapled to the Prime Group’s Lowest Returns on Capital

Independent equity research · June 19, 2026 · Price reference: $294.82 (June 18, 2026 close)

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is general information, not investment advice. The analysis that follows is presented position-free; this opinion block is the single exception, and it carries the only directional valuation view in the piece.

Verdict: HOLD at ~$295 / not-a-short / accumulate-on-weakness in the ~$210–240 zone (~18–21x the FY26 GAAP guide, ~22–24x clean ~$10 normalized EPS, around the base-case low and where the supercycle and Axyv options come closer to free). Do not chase toward the high-$300s. Low-to-medium conviction.

L3Harris is a genuinely good operator wearing a price tag that already credits the win. The operating franchises are real — the tactical-communications business (CSD) is a textbook Greenwald scale-plus-captivity moat earning ~24–25% margins, the highest segment margin in the entire prime peer set; organic growth has inflected hard (+15% in Q1-2026, international book-to-bill 2.2x); and free-cash conversion is excellent (~$3B, ~5.4% FCF yield). But the market is paying a premium EV/EBITDA (~17–18x forward, ~19x trailing) to the higher-quality pure primes (NOC/LMT/GD at ~11–16x) for the prime with the lowest return on capital in the group (~6%, below its ~8% cost of capital). That sub-WACC ROIC is the scoreboard on two full-priced, cycle-top deals — the 2019 L3 merger and the 2023 Aerojet acquisition — that loaded $26.5B of goodwill and intangibles onto the balance sheet and left tangible equity negative. The headline “25.6x” forward P/E also flatters: strip ~$1.40/share of non-operating pension income, ~$0.45 of finite legacy-asset-monetization gains, and a normalizing tax rate, and you are paying ~30–38x clean earnings for a budget-cycle-levered defense prime.

The framing — and I lean on the factor tape here — is not a crowded momentum trade and not a falling knife: beta 0.40, positive alpha (+0.10), a dividend-yield / gold-price (geopolitical-hedge) signature, NOC as its tightest twin (0.889 correlation), now ~22% off a parabolic March-2026 all-time high it reached on supercycle euphoria. This is a quality A&D name digesting a sentiment peak, where the real debate is quality-of-earnings and returns-on-capital, not growth. Conviction is low-to-medium. The single piece of evidence that would flip me bullish: consolidated ROIC visibly grinding toward ~8–9% by 2027–28 as acquired intangibles roll off and organic NOPAT compounds (proving the franchise can out-earn the price paid). The single piece that would flip me bearish: a fixed-price reach-forward EAC charge or a budget air-pocket that exposes the back-half-weighted, pension-and-monetization-flattered EPS ramp and triggers a de-rate toward the pure-prime ~13–16x EV/EBITDA. The tell I keep returning to: in 60 months of filings, not one insider has bought a single share in the open market — not even at the 2023 ~$161 low. Management is happy to be paid in this stock; nobody is buying it.

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACT; attributed causes are INTERPRETATION. No price target, no support/resistance.

The arc. Over the trailing ~5 years LHX round-tripped from post-merger dead money to a parabolic supercycle re-rating and a sharp recent fade. From a ~$161.28 trough (Oct-5-2023) the stock nearly 2.4x’d to a $378.48 all-time high (Mar-2-2026), then gave back ~22% to $294.82 (Jun-18-2026). The 52-week range is $246.65–$378.48; the stock sits ~22% off its ATH, ~20% above its 52-week low, just below its 50-day EMA (~$316.6) and right around its 200-day EMA (~$309). (Source: 5-year daily price history, unadjusted close.)

Cycle narrative. (1) 2021–22 was post-merger dead money — no credit while LHX digested the 2019 L3 deal; the Ukraine spike to ~$271 faded. (2) The Oct-2023 ~$161 low fused the debt-funded Aerojet close, fixed-price program charges, and peak-rate/CR fear — the cyclical trough the bull case is measured from. (3) The +40% recovery into 2024 was a deleveraging-and-self-help story, ahead of any organic acceleration. (4) The mid-2024 give-back was a post-election political wobble (DOGE-cut chatter), not an operating miss. (5) 2025’s +40% re-rating is where the fundamentals turned — organic growth inflected and record orders validated the portfolio. (6) The Jan–Mar-2026 parabola to $378 was the sentiment peak: a guide beating the old framework plus the Axyv/$1B-DoW “unlock” and the promise of a 2028 framework. (7) The drift off the ATH is classic digestion of a ~32x multiple once the Investor-Day catalyst passed. (8) The Jun-18 −6.4% day — the sharpest single move — was a sector-wide unwind of the early-June Iran war-bid on de-escalation, amplified by LHX’s gold/oil factor tilt; no company-specific catalyst was found in the 8-K corpus or news feed.

1. Executive Summary

L3Harris is the #6 US defense prime — a mid-cap “Trusted Disruptor” positioned between the Big-5 (LMT, RTX, NOC, GD, BA) and the venture-backed defense-tech entrants. It is the product of two large deals that define its returns profile: the 2019 “merger of equals” of Harris Corp. and L3 Technologies (~$33–34B all-stock) and the 2023 acquisition of Aerojet Rocketdyne (~$4.7B all-cash). As of fiscal 2026 it reports in three segments: Space & Mission Systems (SMS) — classified space, ISR, missile-warning, maritime, ~mid-10% margin; Communication & Spectrum Dominance (CSD) — tactical radios, EW, night vision, ~25% margin, the crown jewel; and Missile Solutions (MSL/“Axyv”) — solid-rocket motors and munitions, ~mid-12% margin, heading for a 2026 IPO.

The central investment tension is quality-vs-price. On the operating side the story is strong: organic growth has inflected to +15% (Q1-2026), backlog is a record ~$40.7B (1.9x revenue) with a 2.2x international book-to-bill and a ~$25B Munitions Acceleration Council pipeline behind it; FY26 guidance is revenue $23.0–23.5B (+7% organic), segment margin “low 16%,” GAAP EPS $11.40–11.60, and free cash flow ~$3.0B; and the self-help LHX NeXt cost program hit its ~$1B target a year early. But on the capital side the indictment is equally clear: consolidated ROIC is only ~6% — below the ~8% cost of capital and the lowest in the prime group — because $26.5B of goodwill and intangibles from the two deals sit in the invested-capital base (tangible equity is negative, ~−$6.9B). Reported gross margin has fallen ~450bp since 2021 (mix + legacy fixed-price charges), and the GAAP EPS base is flattered by ~$1.40/share of non-operating pension income, ~$0.45 of finite legacy-asset-monetization gains, and an erratic-low tax rate; clean core operating EPS is closer to ~$6.50–7.00.

At $294.82 (~$55B market cap, ~$65B EV), LHX trades at ~25.6x the FY26 GAAP guide — but ~30–38x on clean earnings — and at a premium EV/EBITDA to the higher-ROIC pure primes. A sum-of-the-parts lands at ~$288–307, i.e. at the current price: there is no break-up floor, and the Axyv IPO is a visibility catalyst more than a large value-unlock. The factor tape frames it as a defensive, low-beta, positive-alpha dividend A&D name with a geopolitical (gold/oil) tilt that ran parabolic into the February Investor Day and is now ~22% into a post-peak digestion — not a crowded momentum trade, not a falling knife. The market is underwriting the supercycle correctly and the returns-on-capital and earnings-quality issues too generously. This is a fully-valued, high-quality operator with no margin of safety — an option on a persistent supercycle and an Axyv unlock, not a discount you are paid to own.

2. Business Overview

What it is. L3Harris Technologies (HQ Melbourne, FL; ~45,000 employees, ~18,000 of them engineers/scientists; fiscal year ends the Friday nearest December 31, so “fiscal 2025” = the year ended Jan-2-2026) is a mission-systems and defense-electronics prime serving customers in 100+ countries. Its largest customers are US Government departments and agencies, their prime contractors, and allied governments. It styles itself the “Trusted Disruptor” — deliberately positioned between the legacy primes (it is smaller, faster, more commercial and more of a merchant supplier) and the disruptors (it is a cleared, scaled incumbent with decades of past performance). (FY2025 10-K, Item 1.)

How it was built (the single most important fact for its returns profile). LHX is a roll-up. (1) The 2019 Harris/L3 “merger of equals” (closed Jun-2019) combined legacy Harris (tactical radios) with legacy L3 (ISR, space, maritime, night vision) and created the bulk of today’s ~$26.5B acquired-intangible base. (2) The 2023 Aerojet Rocketdyne acquisition (~$4.7B, $58.00/share all-cash, closed Jul-28-2023) added solid-rocket-motor (SRM) propulsion. It is therefore an assembled portfolio, not an organically grown one — and the price paid to assemble it is why reported ROIC is the lowest in the peer set (§5, §6).

The new three-segment structure (effective fiscal 2026; first reported Q1-2026 10-Q). LHX collapsed its old four-segment structure (CS / IMS / SAS / Aerojet) into three, grouped by business model:

• Space & Mission Systems (SMS) — Q1-26 revenue $2,990M (+24% YoY), op margin 10.5%, backlog $21.1B. The “traditional prime” leg: airborne ISR / missionized special-mission aircraft (Compass Call), space payloads and satellites (SDA tracking layer, missile warning), maritime (naval sensors, autonomous undersea), FAA air-traffic networks, and classified intel & cyber. Lowest-margin, most cost-type, most classified.
• Communication & Spectrum Dominance (CSD) — Q1-26 revenue $1,855M (+3% YoY), op margin 25.1% (~24% clean of a $20M one-time legal settlement), backlog $9.1B. The crown jewel: software-defined tactical radios and waveforms (an installed base of ~1M radios), electronic warfare (Next Gen Jammer), tactical data links, EO/IR and counter-UAS (VAMPIRE), and night-vision goggles/image-intensifier tubes. Most international (~41%), highest-margin, product-and-installed-base-driven.
• Missile Solutions (MSL) — Q1-26 revenue $990M (+18% YoY), op margin 12.5%, backlog $10.5B. The Aerojet inheritance: missile propulsion (SRM for interceptors, strategic deterrence, precision strike), advanced effects (guidance/seekers/weapons-release), and civil-space propulsion. ~75% subcontractor — a merchant SRM supplier to LMT and RTX. LHX has filed a confidential S-1 to IPO MSL as “Axyv” in 2026, anchored by a $1.0B Department of War convertible-preferred investment.

How it makes money. Revenue is recognized percentage-of-completion on long-duration government programs. The contract mix is ~75% fixed-price (firm-fixed or fixed-price-incentive — LHX bears overrun risk, the source of its legacy EAC charges) and ~25% cost-type (reimbursed cost + capped fee). This is the highest fixed-price share in the prime group (LMT ~60%), a structural reason its gross margin sits below peers and it carries more execution/inflation risk. By customer relationship it is ~64% prime / ~37% subcontractor — meaningfully more of a merchant supplier than any Big-5 prime: it both competes with and sells subsystems into BAE, Boeing, GD, LMT, NOC, RTX, and Thales. (FY2025 10-K, Note 14 disaggregation; Item 1 Government Contracts.)

Customer mix. FY2025: ~75% of revenue from the US Government (directly or via primes, including foreign military sales); ~22% international end-customer ($4.8B, no single foreign country >5%); ~28% classified. No single customer other than the USG exceeds 5%. (FY2025 10-K; Q1-26 call.)

Recurring vs program. Revenue is overwhelmingly long-duration program work, “recurring” only in the sense of ~1.9x backlog coverage (≈40% converts within 12 months, ≈65% within 24). There is no high-margin commercial-aftermarket annuity comparable to RTX or GE engines; the closest thing to annuity economics is the tactical-radio installed base (sustainment, waveform upgrades, refresh cycles) in CSD.

§2 Verdict. A mid-cap, acquisition-assembled defense prime with a genuinely differentiated three-leg portfolio — a high-margin communications franchise, a lower-margin classified space/ISR integrator, and a merchant SRM business heading for a partial IPO. The “Trusted Disruptor” identity is real, not just marketing: LHX is structurally more fixed-price, more international, more merchant-supplier, and more classified than the Big-5 — its differentiation and its risk. The defining caveat: the whole edifice rests on $26.5B of acquired intangibles, so even good operating businesses produce mediocre returns on capital.

3. Industry Dynamics

Structure: a high-barrier oligopoly serving a monopsony buyer. A handful of primes compete for programs that take years to bid (and are subject to bid protests) and lock in the winner for a program’s multi-decade life. Entry requires security clearances, ITAR-controlled technology, a cleared workforce, qualified facilities, and a multi-decade past-performance record — assets no new entrant can quickly assemble. This is the single fact that governs the whole group. (Greenwald barriers-to-entry lens; cross-referenced against comparable defense primes NOC, GD, RTX, LMT.)

The monopsony return ceiling. The same barriers that protect incumbents hand the single buyer enormous leverage. Through the Defense Contract Audit Agency, truth-in-negotiations rules, cost-accounting standards, and progress-payment mechanics, the government structurally caps prime operating margins in the ~10–11% range — far below what the barriers alone would allow. This is why the entire group earns ~10% operating margins and low-teens ROIC (GD ~13%), not software-like returns: the moat is real, but the landlord takes most of the rent.

Demand: a genuine multi-vector supercycle — the strongest setup in a generation.

• US budget. GFY2026 Defense Appropriations of $859B were signed Feb-3-2026. The GFY2027 President’s Budget Request (~Apr-2026) targets a ~$1.5T national-defense topline (~$1.1T base + ~$350B in a second reconciliation bill). The Jul-4-2025 reconciliation package already added $155B for national defense (≈$25B earmarked to Golden Dome). (Q1-2026 10-Q, U.S. and International Budget Environment.) Critical caveat: the FY27 number is a request until appropriated — the single largest near-term swing factor.
• NATO/allied rearmament. Almost all NATO allies committed to 5% of GDP over the next decade (3.5% core + 1.5% infrastructure). LHX is the most internationally-levered prime (CSD ~41% international) and a direct beneficiary via radios, EW, and night vision; international book-to-bill was 2.2x in Q1-26.
• Munitions / SRM replenishment. Post-Ukraine/Middle-East depletion is driving multi-year interceptor and SRM demand; LHX’s MSL is one of only two scaled US SRM makers (the other is NOC’s Orbital ATK-derived business).
• Golden Dome. The US homeland missile-defense architecture — LHX is positioned across missile-warning/tracking (SDA, HBTSS-class), C2, and interceptor propulsion.
• Iran/Middle-East conflict (Jun-2026). US retaliatory strikes (Jun-9), the Defense Production Act invoked for munitions (Jun-16), and GM/RTX/LHX munitions-output talks (Jun-17) produced a near-term bid — and the likely “sell-the-news” trigger for the −6.4% Jun-18 day on de-escalation.

Procurement reform — double-edged. The DoW is streamlining acquisition (the “Warfighting Acquisition System”): delegated authority, expanded Other Transaction Authority (FAR-exempt), commercial solutions, and the Munitions Acceleration Council framework (~$25B pending). LHX frames its “Trusted Disruptor” speed/affordability positioning against this backdrop — but its own 10-K warns that OTAs “could reduce barriers to entry and result in even greater competition and increased pricing pressure,” explicitly favoring non-traditional entrants (Anduril and the like). Reform is a tailwind for incumbents that move fast and a moat-eroder if it succeeds in lowering entry barriers — and LHX, the most merchant/OTA-exposed prime, sits on both edges. (FY2025 10-K, Item 1A lines 205–208.)

Marathon capital-cycle read. Across most of A&D the normal mean-reversion mechanism — high returns attract capital that competes margins away — is structurally blocked: private capital cannot will a cleared SRM plant or a classified satellite line into existence. The one place the cycle is genuinely active is exactly where LHX is most exposed: munitions/SRM and space, where the government itself is deliberately funding capacity (the $1.0B DoW investment in MSL; NOC qualifying as a PAC-3 SRM second source; the DPA invocation; a wave of defense-tech IPOs and LHX’s own Axyv IPO). This is rational while visibility is high, but it is a textbook capital-cycle warning: government-manufactured competition plus capital flooding into munitions/SRM/space is the place to watch for eventual over-supply if the geopolitical cycle turns. That LHX is IPO-ing its fastest-growing leg into a hot market is itself a mild “sell the cyclical at the top” tell.

Budget mechanics as recurring friction. The US rarely passes appropriations on time; continuing resolutions (fund at prior-year levels, bar new starts) are the norm, and shutdowns add award-timing and working-capital volatility — a perennial source of “the backlog is there but the funding slipped” disappointments. The FY25 government shutdown, in management’s own words, “delayed awards and limited additional revenue growth.”

§3 Verdict: structurally good industry, with the group’s usual asterisk — and LHX sits in a slightly riskier seat than the Big-5. Barriers to entry are extraordinary, the capital cycle is mostly blocked, demand visibility is multi-decade, and the supercycle is genuine. But the monopsony caps returns at ~10–11% margins / low-teens ROIC, the FY27 budget is a request not law, and CR/shutdown timing is perennial. The LHX-specific nuance: it is the prime most levered to the two places the capital cycle is active (munitions/SRM and space, where the buyer is funding capacity and second sources) and the most exposed to procurement reform’s entry-barrier-lowering edge. Good industry; LHX is not in its safest neighborhood (contrast NOC’s nuclear-triad seat).

4. Competitive Position

Greenwald requires naming the moat mechanism per segment and tying it to a financial outcome that would deteriorate without it. LHX’s three segments have three different moats of three different widths — and only one passes the financial test cleanly.

CSD (tactical comms / EW / night vision) — the REAL moat: economies of scale + customer captivity + switching costs. This is the franchise. Legacy Harris is the dominant Western maker of military tactical radios, with an installed base of ~1M radios running proprietary, NSA Type-1-certified waveforms. The moat is Greenwald’s strongest type — economies of scale (the largest share of a defined market amortizes waveform R&D, crypto certification, and production base over the most units) combined with customer captivity (switching costs: interoperability, retraining, recertification, and the catastrophic risk of a non-interoperable radio in combat). Competitors are Collins (RTX) and Thales internationally, plus emerging mesh-radio entrants like Silvus. The moat shows up in the financials: CSD’s ~24–25% operating margin is roughly 2.5x the company average and the highest segment margin in the entire prime peer set — that is franchise rent, and it would deteriorate sharply if the installed-base/standards lock broke. This passes the market-share-stability and ROIC tests. Watch item: the DoD’s own push toward software-defined/open-architecture radios, plus well-funded entrants, are the long-run threat to those switching costs. (Q1-26 10-Q CSD margin; FY2025 10-K competitors.)

SMS (space / ISR / classified) — incumbency + past-performance, but THINNER (and it shows). The moat here is qualification/intangibles + spec-in switching costs + classified past-performance (you cannot bid a classified program without the clearances and the record). LHX is a credible #2/#3-tier space/ISR integrator (SDA tracking-layer satellites — the only firm on all four tranches — missionized special-mission aircraft, missile-warning). But this is a contested arena: it competes head-to-head with NOC (#1/#2 space), LMT, and increasingly SpaceX/Anduril/new-space on satellites and ground systems, and against everyone on ISR aircraft. The thinness shows in the numbers: SMS earns only ~10.5% — barely above the monopsony floor — and is the most cost-type, lowest-pricing-power segment. The moat is “you’re already in and cleared,” not “no one else can do this” — past-performance incumbency is the weakest of Greenwald’s barriers, closest to qualification, which second-sourcing erodes.

MSL (solid rocket motors / missiles) — a genuine SCARCITY/qualification moat, but a MERCHANT one the buyer is deliberately diluting. Aerojet makes LHX one of only two scaled domestic SRM suppliers (the other is NOC/Orbital ATK). SRM is a true qualification + scale + hazardous-facility barrier — you cannot stand up a new energetic-materials plant quickly or cheaply, and every interceptor is qualified to a specific motor. That is a real moat, and the munitions supercycle is monetizing it (MSL +18% organic, $25B MAC pipeline). But three things narrow it: (1) LHX is a merchant supplier (~75% subcontractor) — it sells SRM into LMT/RTX missiles, so its pricing power is capped by its prime customers and the monopsony behind them; it is a price-taker squeezed from both sides. (2) The government is deliberately funding second sources and new capacity (the $1.0B DoW investment, NOC qualifying as a PAC-3 second source, the DPA) — manufacturing competition into a structure that would otherwise be a duopoly: the precise Marathon warning. (3) MSL’s margin is only ~12.5% and carries legacy EAC risk (a −$31M Q1-26 naval-sensor charge). The Axyv IPO will crystallize a value for it — and arguably LHX is monetizing it at the cyclical peak.

Direct comparison vs peers.

• vs NOC (closest factor twin, 0.889): NOC owns the two best seats in defense (B-21 + Sentinel ICBM monopolies, nuclear-triad-protected) and a ~15%-margin Mission Systems electronics moat. LHX has no comparable sole-source mega-monopoly but has a higher-margin comms franchise (~24% vs ~15%) and more diversification. NOC is the safer, more strategically-insulated bet; LHX is higher-margin at the franchise level but lower-ROIC overall.
• vs LMT: LMT’s moat is sole-source installed-base incumbency (F-35, missiles), and it bleeds when it competes on fixed-price (~$3.6B of 2024–25 charges) — proof its edge is incumbency, not execution. LHX is more fixed-price (75% vs 60%) yet has avoided LMT-scale reach-forward losses, suggesting better execution discipline on smaller programs — but it has no F-35-class annuity.
• vs GD: GD has the submarine duopoly, sole-source Abrams/Stryker, and Gulfstream — a clean, charge-free book at ~13% ROIC. LHX is messier (huge goodwill, fixed-price EAC history) but has higher-margin comms vs GD’s low-margin IT.
• vs RTX: RTX has the commercial-aftermarket annuity LHX lacks; both compete in missiles/EW/comms (Collins vs CSD).

The ROIC reconciliation (the key competitive fact). LHX’s reported ROIC is only ~6%, materially below NOC/LMT/GD (low-teens-to-high-20s) and below WACC. Is this a real quality gap or a goodwill artifact? Mostly the latter, but not entirely. The dominant driver is the $26.5B acquired-intangible base — ROIC’s denominator is loaded with goodwill the operating businesses (which earn 10.5–25% segment margins) did not have to build; the return gap is a capital gap, not a margin gap. Segment operating margins (FY25 ~15.4% blended; Q1-26 15.7%) are perfectly competitive. But it is not purely cosmetic: the low ROIC is the literal scoreboard saying LHX paid full price for these businesses (L3 at a 2019 high, Aerojet at $58 in 2023), so shareholders own good operating cash flows at an inflated invested-capital base. Tangible book is negative (~−$6.9B). Ex-goodwill ROIC is ~18% and cash ROIC ex-goodwill ~25% — i.e., the operating businesses earn high returns on the tangible capital they actually employ; the purchase price consumed much of the franchise value up front.

§4 Verdict: genuine but uneven moats — one wide (CSD), one thin (SMS), one real-but-shared-and-deliberately-diluted (MSL) — delivering competitive segment margins but mediocre returns on a goodwill-inflated capital base. LHX owns a better collection of operating franchises than its ~6% ROIC suggests, but it paid full price to assemble them, so the moat shows up in segment margins, not in shareholder returns on capital. Narrower than the “Trusted Disruptor” bull case implies on SMS and MSL; wider than acknowledged on CSD.

5. Growth History and Forward Opportunities

History. Revenue: $18.19B (2020) → $17.81B (2021) → $17.06B (2022) → $19.42B (2023) → $21.33B (2024) → $21.87B (2025). The honest read: LHX shrank in its first three post-merger years (−6% 2020→2022, on budget plateau, COVID, and divestitures), and the 2023–24 step-up was substantially the Aerojet acquisition (AR/MSL revenue $1.24B in 2023 → $2.58B in 2024 → $2.85B in 2025) plus the budget upcycle — not underlying organic compounding. Stripping Aerojet, the legacy business was roughly flat-to-low-single-digit through 2024. FY25 reported growth (+2.5%) was further depressed by the Mar-2025 CAS disposal-group divestiture (~−$0.8–1B revenue). (FY2025 10-K Note 14; Q1-26 10-Q.)

The organic inflection is new — and real. The run-rate accelerated to +15% organic in Q1-2026 (SMS +24%, CSD +3%, MSL +18%) — and, critically, this acceleration appears genuinely organic and demand-driven (classified/space ramps, munitions volume, international comms), not acquired. The quality of growth is improving in real time: the prior acquisitive growth destroyed return-on-capital; the current organic growth is higher quality.

Backlog / book-to-bill. Contractual backlog $40.7B at Q1-2026 (~1.9x revenue, up from $38.7B at FY25-end), ~40% converting within 12 months and ~65% within 24. Q1-26 total book-to-bill 1.4x, international 2.2x — the standout. By segment: SMS $21.1B, MSL $10.5B, CSD $9.1B. Behind backlog sits the ~$25B Munitions Acceleration Council (MAC) pipeline (SRM orders pending), with management flagging backlog could reach $60–70B within 12 months if MAC books.

Guidance & frameworks. FY2026 guide: revenue $23.0–23.5B (~7% organic midpoint), segment operating margin “low 16%,” GAAP EPS $11.40–11.60, FCF ~$3.0B. The FY26 segment framework (Q4-25 call): SMS ~$11.5B at mid-10%; CSD ~$8B at ~25%; MSL ~$4.4B at mid-12% (~$620M EBITDA). Open item (handled honestly): management’s longer-term “2028 financial framework” was unveiled at the Feb-25-2026 Investor Day; the specific 2028 targets circulated publicly (~$25–26B revenue, ~16%+ segment margin, ~$13–14 EPS, ~$3.4B FCF) are investor-relations-deck-sourced, not in the SEC filings or earnings-call transcripts — they are treated here as management guidance/interpretation, not audited fact. (Q4-25 call confirms the framework’s existence and venue; it did not exist in any filing as of the Jan-29-2026 call.)

Key funded growth drivers. SMS: Compass Call / missionized special-mission ISR business jets, SDA Tranche-3 satellites, classified space, FAA air-traffic modernization (funded by $12.5B FAA reconciliation + $22B appropriation), missile-warning/tracking (Golden Dome). CSD: Next Gen Jammer EW ramp, the next-gen “Falcon” software-defined radio family, counter-UAS (a $106M Army VAMPIRE order Jun-2026), night vision. MSL: SRM ramp, the MAC pipeline, Golden Dome interceptors. LHX has also cut strategic partnerships with Palantir, Anduril, Shield Capital, and Amazon Kuiper — an “if you can’t beat the disruptors, partner with them” hedge against the OTA/new-entrant threat.

Quality of growth. Durable and largely funded, but budget-cycle-dependent and partly cyclical. Positives: backlog 1.9x, international book-to-bill 2.2x, organic acceleration to +15%, programs aligned to the most-protected budget lines (munitions, Golden Dome, space, NATO comms). Caveats: (1) the FY27 budget is a request; (2) a meaningful slug of munitions/SRM growth is replenishment-cyclical and sits exactly where the capital cycle is most active (over-supply risk on de-escalation — note Jun-18); (3) MAC’s $25B is a pipeline, not booked backlog; (4) the MSL IPO removes the fastest-growing leg from full ownership.

§5 Verdict: a high-quality organic inflection replacing a low-quality acquisitive past — real and funded, but riding a budget/munitions cycle near its peak. The pre-2025 growth was largely merger/Aerojet arithmetic that destroyed return-on-capital; the 2025–26 acceleration is genuinely organic, demand-driven, and aligned to the most-protected priorities — the best growth setup in LHX’s history as a combined company. The discipline is to recognize that the strongest drivers are also the most cyclical and the most exposed to government-funded over-supply, and that the FY27 budget underpinning it remains a request. Durable for the next 1–2 years; cyclically exposed beyond that.

6. Financial Quality

Revenue composition. Covered in §5 — a meaningful slice of post-2022 “growth” is acquired (Aerojet) and cyclical (the budget upcycle), distinct from the secular-compounder framing the multiple implies; the genuinely organic acceleration is recent (Q1-26 +15%).

Gross-margin compression — decomposed. Gross margin fell ~450bp: 30.2% (2021) → 28.9% (2022) → 26.3% (2023) → 25.9% (2024) → 25.7% (2025). The step-down is concentrated 2021→2023, not recent. Two-thirds is mix — folding the ~9.5%-margin Aerojet/propulsion segment into a ~25–28% legacy mix mechanically drags consolidated gross margin — and roughly one-third is legacy-L3 fixed-price EAC losses + inflation on multi-year contracts signed pre-2022 (net EAC adjustments swung from −$85M operating income in FY23 to +$47M in FY25). The compression is largely structural, not a transient that fully reverses. (FY2025 10-K MD&A and segment results.)

The gross-margin-down vs segment-margin-up paradox. Consolidated GAAP gross margin is compressing (25.7%) while management guides segment operating margin rising to “low 16%.” These reconcile: segment operating margin is struck below the line that strips out ~$769M of acquired-intangible amortization, ~$167M of LHX NeXt restructuring, and divestiture losses, all parked in “Unallocated Corporate Items.” The LHX NeXt cost-takeout (~$1B, hit a year early) is genuinely lifting segment margins even as mix drags gross margin.

The 2026 reporting change — an apples-to-oranges trap. Effective fiscal 2026, LHX reports GAAP (not non-GAAP) segment operating income and GAAP EPS, and the FY26 GAAP EPS guide ($11.40–11.60) is up sharply from the FY25 GAAP print ($8.52). Investors must not naively compare the two — part of the ~$3 jump is the reporting-basis change and intangible-amortization roll-off, not pure operating growth.

Quality of earnings — how much EPS is “real” operating? FY25 GAAP diluted EPS of $8.52 is materially flattered below the operating line:

• Pension. Non-service FAS pension income and other was +$419M (≈22% of operating income, ~$1.40/share pre-tax) — a non-operating, market-driven, non-cash credit that can reverse with rates and asset returns.
• Tax. The effective rate is erratic and abnormally low: 1.9% (2023), 5.3% (2024), 16.9% (2025). FY23/24 EPS were artificially boosted by ultra-low rates; the normalization up in FY25 actually masks underlying operating improvement.
• Legacy-asset monetization. A recurring G&A credit — “monetization of certain legacy end-of-life assets” — was +$184M (FY25) vs +$62M (FY24), padding operating margin with finite gains (~$0.45 pre-tax EPS). The 3x jump is a quality-of-earnings flag.

Stripping pension and monetization and normalizing tax, clean core operating EPS is closer to ~$6.50–7.00, vs the $8.52 GAAP print. EPS growth into 2026 is partly real (LHX NeXt margin, organic volume) but materially flattered by the reporting switch, amort roll-off, pension, and monetization.

FCF and capital intensity — the strongest part of the profile. FY25 operating cash flow ~$3.1B; capex is light (~$0.4–0.5B; depreciation $453M), so FCF ≈ OCF (~$16.6/share); FY26 guide $3.0B. Working capital is seasonal (Q1-26 FCF was −$187M — do not annualize). FCF/NI conversion is high (~190%) because D&A (including $769M of non-cash intangible amortization) and pension net to large add-backs. The high conversion is genuine and is what funds the dividend, buyback, and deleveraging — but note it partly reflects the same non-cash items (intangible amort from full-priced M&A) that depress GAAP earnings: it is the “return of” the acquisition premium, not pure economic earnings.

ROIC ~6% — sub-WACC — the central economic fact. Computed check: NOPAT = EBIT $2,110M × (1 − 16.9%) = $1,753M; invested capital = net debt $10,050M + equity $19,600M = $29,650M; ROIC = 5.9%, against an A&D WACC of ~7.5–8.5%. It is a denominator problem: invested capital carries $20.0B goodwill + $6.5B acquired intangibles = $26.5B of acquisition premium. Ex-goodwill ROIC is ~18%; cash ROIC ex-goodwill ~25% — the operating business earns very high returns on the tangible capital it employs. The Greenwald/Marathon synthesis: a good business whose franchise value was largely paid away to the sellers in two scale acquisitions, so the blended enterprise earns below its cost of capital.

Balance sheet & leverage. FY25 total assets $41.2B, of which $26.5B (64%) is goodwill + intangibles; total equity $19.6B but tangible equity negative (~−$6.9B), so P/TBV is not meaningful. Net debt $10.05B (~3x EBITDA gross, ~3.0x net), reduced from a post-Aerojet peak of ~$13.4B; investment-grade (BBB / Baa range), $3B undrawn revolver, no covenant issues. Deleveraging is disciplined and credible.

§6 Verdict — do economics improve with scale? No, not at the enterprise level, and that is the indictment. The operating business is high-quality (high tangible ROIC, capital-light, ~190% FCF/NI conversion, sticky sole-source backlog, LHX NeXt lifting segment margins). But the enterprise earns ~6% ROIC — below cost of capital — because management bought scale with ~$26.5B of goodwill/intangibles, and consolidated gross margin actually fell ~450bp as it added lower-margin mix. Scale was bought, not earned. EPS growth is partly real but materially flattered by pension, finite monetization gains, a low/erratic tax rate, the 2026 reporting switch, and amort roll-off. The profile is “good franchise, sub-WACC blended returns, high-quality cash conversion” — a quality-vs-price tension, not a clean compounder.

7. Capital Allocation

The two defining deals (Marathon lens).

1. 2019 L3-Harris “merger of equals” (~$33–34B all-stock, closed Jun-2019). Strategically coherent — it built a genuine #4 prime with scale in tactical comms and ISR, sold on ~$500M of cost synergies. But it was an all-stock combination at scale near a defense-cycle high; the goodwill it created is the bulk of today’s return-on-capital drag, shares were issued as the currency, and consolidated ROIC has sat ~6% since. Per-share value creation is debatable.
2. 2023 Aerojet Rocketdyne (~$4.7B EV, $58.00/share all-cash, closed Jul-2023). Vertical integration into SRM propulsion — strategically defensible as the only credible #2 source vs Northrop, given the munitions supercycle. But ~$4.7B for ~$2.2B of revenue (~2.1x sales) at ~9.5% margins is a full price for a capacity-constrained, capital-hungry asset, bought with debt (driving leverage to ~3.5x). On consolidated ROIC math it has not yet earned its cost of capital; the bull path (the $25B MAC pipeline + $1B DoW capacity investment) is prospective, policy-dependent, and unproven.

Both deals are strategically sensible and operationally integratable, but each was struck at a full price near a cycle high and financed in ways that mean returns-on-capital have not validated the prices. This is the core verdict: empire-building dressed in good strategic logic, with value accruing to the sellers.

Deleveraging. Correctly prioritized post-Aerojet: net debt $13.4B (2023) → ~$11.1B (2025), with $600M of notes retired in FY25; target net leverage ~3x trending toward ~2.5x. Disciplined.

Buybacks. Repurchases $3.68B (2021) → $1.08B (2022) → minimal in 2023 (integration/deleveraging) → $0.55B (2024) → $1.15B (2025); shares 214M (2020) → 187M (2025), −12.6%. Timing has been acceptable-to-good (2021 at ~$200–215, 2025 at ~$210–260) — a genuine positive, though dwarfed by the goodwill created in M&A.

Dividend. ~$0.90B/year, ~56% payout of GAAP EPS, ~1.7% yield at $295 — sustainable on $3B FCF; a long-standing grower (legacy Harris raised for 20+ consecutive years; the combined entity has continued annual increases — the exact streak is left as an open item pending IR confirmation).

The 2026 un-conglomeration. Three moves, none yet in guidance: (a) the 60% sale of civil Space Propulsion & Power (SPPS) to AE Industrial Partners — which triggered an $85M FY25 goodwill impairment, a small admission the 2023 price was full; (b) the $1B DoW convertible-preferred into MSL (converts at a 20% discount to the IPO price + 3% premium-priced warrants; DoW takes a single-digit, purely economic stake); and © the confidential S-1 to IPO MSL as “Axyv” (JPMorgan/Morgan Stanley underwriters), a “$4B-plus revenue, majority-owned public company” that remains a consolidated LHX segment. The same management that spent ~$38B acquiring scale in 2019–2023 is now carving and IPO-ing pieces ~3 years later. Charitably, rational SOTP value-surfacing into a hot market; skeptically, financial engineering — buy propulsion at a full price, carve/IPO pieces at a higher multiple, monetizing the cycle rather than earning durable returns on the consolidated base. Value-creative only if the IPO/sale marks exceed the consolidated multiple and proceeds deleverage or buy back stock.

Incentive alignment (2026 DEF 14A). Annual incentive: four financial metrics — Free Cash Flow, EBIT, Revenue, and Segment Operating Margin (Revenue is the one mild empire/top-line flag, but it is one of four and balanced by margin/FCF). Long-term PSUs (3-year): 33% cumulative EPS / 33% average ROIC / 33% relative TSR — an above-average plan that explicitly rewards ROIC (the metric the central flaw concerns) and aligns to shareholders via relative TSR. CEO Christopher Kubasik (combined Chairman + CEO — a governance concern) earned FY25 total compensation of $25.6M (+23% YoY, tracking the TSR re-rating).

§7 Verdict — has management allocated capital intelligently? Mixed, leaning negative on the big decisions. The two franchise-defining deals were strategically coherent but struck at full prices near cycle highs and financed in ways that drove consolidated ROIC to ~6% (sub-WACC); value largely accrued to the sellers. The 2026 un-conglomeration is part rational pruning, part cycle-monetizing financial engineering, and a tacit admission the roll-up under-delivered per-share value. The redeeming features are real — disciplined deleveraging, acceptable-to-good buyback timing, a sustainable growing dividend, and a genuinely above-average comp plan. Net: competent stewardship of cash flow and the balance sheet; poor-to-questionable stewardship of the big strategic-capital decisions.

8. Changes and Headwinds — Last Two Years

The trailing two years are the busiest portfolio/structural period in LHX’s history as a combined company — a deliberate pivot from “acquire to build scale” (2019–2023) to “reorganize, prune, and monetize” (2024–2026).

1. Segment reorganization, 4 → 3 (effective fiscal 2026; 8-K Jan-5-2026). The old CS/IMS/SAS/Aerojet structure was collapsed into SMS, CSD, and MSL, grouped by business model — precisely to make MSL cleanly carve-out-able for the IPO and to spotlight CSD’s ~25% commercial margins. Structural pre-work for the un-conglomeration, not cosmetic.

2. C-suite & segment-leader turnover. CFO Ken Bedingfield moved to President, Missile Solutions (to run the IPO business); Ken Sharp joined as CFO mid-Mar-2026. Concurrently, Sam Mehta (ex-Collins/RTX) was appointed President of both SMS and CSD, while the prior CSD President (Jonathan Rambeau) departed. A CFO change mid-supercycle plus a segment-president departure plus consolidation of two segments under one new-to-LHX leader is meaningful continuity/key-person risk right as the company executes its most complex-ever portfolio surgery. Sending the CFO to run the carve-out is a credibility signal for the IPO but thins the holdco finance bench at the worst moment — watch for accounting-conservatism/guidance shifts under Sharp.

3. Portfolio reshaping — the un-conglomeration (the 60% SPPS sale to AE Industrial, the $1B DoW preferred, the Axyv IPO) — detailed in §7. Marathon read: rational SOTP value-surfacing and a textbook “monetize the cyclical near the top” tell.

4. LHX NeXt completed early. The ~$1B cost-takeout hit its target a full year ahead of plan and is now folded into ongoing operations (“part of our DNA”). It genuinely lifted segment margins toward “low 16%” — a real, if largely-banked, positive; the incremental future tailwind is now smaller.

5. Aerojet integration stabilizing. MSL delivered three consecutive quarters of double-digit organic growth into Q4-25 (12% FY25, >$2.8B revenue, 12.5% margin), with management “clearing delinquent rocket-motor deliveries dating back to the acquisition.” The integration risk that dogged 2023–24 is receding; execution is the new story. But legacy EAC risk remains (the −$31M Q1-26 charge).

6. Backlog doubling + MAC pipeline. Backlog $38.7B (FYE-25) → $40.7B (Q1-26), ~1.9x revenue; FY25 book-to-bill 1.3, Q1-26 total 1.4 / international 2.2. Marquee wins: $2.2B South Korea AEW&C, ~$850M SDA Tranche-3, >$2B international special-mission jets, $106M VAMPIRE counter-UAS. Plus the ~$25B MAC pipeline (a pipeline, not backlog — and partly replenishment-cyclical, the exposure that sold off Jun-18).

7. Budget/political environment — generational tailwind, but request-dependent. GFY2026 appropriations $859B (signed Feb-3-2026); the Jul-2025 reconciliation added $155B; the FY27 PBR targets ~$1.5T; NATO to 5% of GDP; the Jun-2026 Iran escalation and DPA invocation. Headwinds/caveats: FY27 is a request until appropriated; CR/shutdown timing is perennial friction (the FY25 shutdown “delayed awards”); some FY26 line items (certain HMS radios, Armed Overwatch) were cut in the request; OBBBA tax changes add EPS volatility; OTAs cut both ways.

§8 Verdict: on balance strengthen the thesis operationally, but raise execution/complexity/cycle risk — and the biggest swing factors are exogenous (budget) and cyclical (munitions). The operational changes are genuinely positive (LHX NeXt early, Aerojet stabilizing, record backlog, transparency). The portfolio surgery can surface SOTP value but stacks IPO execution + a fresh CFO + segment-leader churn on the most complex restructuring in company history, and tacitly concedes the 2019–2023 roll-up under-delivered. The demand environment is the best in a generation but rests on a request-stage FY27 budget and a munitions cycle the buyer is deliberately over-supplying. Net: strengthens the 1–2 year thesis, modestly weakens the through-cycle one.

9. Risk Analysis (Risk Matrix)

Synthesis. The high-impact / medium-likelihood cluster that defines the downside is budget/CR cyclicality (1), fixed-price EAC charges (2), valuation de-rate (11), and back-half-weighted execution (6). The distinctive LHX risks vs the Big-5 are the fixed-price concentration (highest in the group), the merchant-SRM second-sourcing squeeze (9), the EPS-quality/pension reliance (8), and the Axyv-separation complexity (7) — none individually catastrophic, but collectively they explain why a premium-multiple, sub-WACC-ROIC prime carries more de-rate risk than its returns justify. Catastrophic/total-loss risk is very low (IG balance sheet, 2x backlog, a monopsony buyer that does not default). The profile is “many medium cracks, no single fatal flaw” — appropriate for a name priced for success.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation. Scenarios are scenarios, not targets.

Anchor. At $294.82 (Jun-18-2026): ~187M shares → market cap ~$55.1B; net debt ~$10.05B → EV ~$65.1B.

The two-P/E problem (the central valuation question). LHX trades at two very different P/Es, and the gap is the thesis:

• On the FY26 GAAP guide ($11.50 midpoint): ~25.6x — the number the “premium compounder” narrative quotes.
• On clean core operating EPS (~$6.75): ~43.7x (range ~42–45x) — stripping ~$1.40 pension income, ~$0.45 finite monetization gains, and normalizing tax.

Which is the market paying? The honest answer: ~25–26x a 2026 number that is itself partly manufactured. The ~$3 jump from the $8.52 FY25 GAAP print is inflated by the reporting-basis switch, intangible-amort roll-off, a normalizing tax rate, lower net interest, and back-half weighting (Q1 was only $2.72, implying ~$8.78 over Q2–Q4 — a steep ramp). On genuinely clean, normally-taxed operating earnings (giving credit for LHX NeXt and 2026 volume but stripping pension/monetization, call it ~$7–8), LHX trades at roughly 30–38x — a growth multiple on a sub-WACC-ROIC, budget-cycle-levered prime. The headline 25.6x understates how richly the clean business is priced.

EV-based multiples. EV/EBITDA 19.3x trailing on GAAP EBITDA ($3.37B); ~23x on a cleaner EBITDA (stripping non-service pension and monetization); ~17–18x forward. EV/Sales ~3.0x trailing, ~2.8x forward. EV/EBIT 30.3x trailing. FCF yield ~5.4% (the most flattering metric and the strongest part of the profile — but it includes the non-cash amort that is effectively the “return of” the M&A premium).

Own-history context. Own-history valuation percentiles: P/E 32.0x = 69.9th, P/B 2.82x = 62.8th, P/S 2.47x = 65.9th, composite 66th — moderately rich vs its own history, not the 85th–90th of RTX/HWM, not cheap. (P/TBV is meaningless — tangible equity is negative.)

Peer placement.

On EV/EBITDA and clean P/E, LHX trades at a clear premium to the pure primes (NOC/LMT/GD at ~11–16x) and roughly in line with RTX — yet has the lowest ROIC in the group. On pure quality-vs-price math this is hard to justify: you are paying a prime-premium multiple for the prime with the worst returns on capital. The offsets the bulls cite — the highest defense-growth beta, the highest-margin segment franchise (CSD), and Axyv/SOTP optionality — are real but are the upside option, not a discount.

Sum-of-the-parts (the Axyv catalyst). Annualized segment revenue: SMS ~$11.96B, CSD ~$7.42B, MSL ~$3.96B. Valuing CSD (~24% margin, scale+captivity) at ~16x EBITDA (~$34.7B EV), SMS (low-margin integrator) at ~11x (~$20.7B), and MSL/Axyv (merchant SRM, supercycle) at ~15–20x (~$10.5–14.1B) gives total EV ~$66–69.5B, less ~$10.05B net debt and ~$2B corporate-cost drag → equity ~$54–57B → ~$288–307/share, essentially at the current price. There is no break-up floor — the market already values LHX on a parts basis. The one source of SOTP upside is the Axyv IPO crystallizing a richer public mark on MSL (a pure-play munitions/SRM IPO could fetch 18–25x EBITDA / 3–4x sales = ~$12–16B EV) — an implied uplift of perhaps ~$10–20/share, offset by stranded/dis-synergy costs and loss of full ownership. The SOTP is a catalyst for visibility, not a large value-unlock.

Embedded expectations / reverse-DCF. At $55.1B equity / $3.0B FCFE, a Gordon-growth reverse-DCF implies the market is underwriting only ~3.1–3.6% perpetual FCFE growth (at 8.5–9% cost of equity) — roughly the defense-sector long-run norm and below the near-term ~7% organic guide. The market is not pricing the supercycle into perpetuity; expectations are modest, which is the bulls’ best argument that the multiple is defensible. The catch: that math assumes the ~$3.0B FCF and ~16% segment margins are sustainable (not cyclically peak) and that you accept a sub-WACC-ROIC enterprise at a ~3.6% terminal growth. To justify $295 on a returns basis, LHX must either (a) grow FCF durably to ~$3.5–4.0B by 2028 and lift consolidated ROIC toward ~8–9% as goodwill amortizes and organic growth out-earns the acquisition base, or (b) execute the Axyv/SOTP value-crystallization.

Scenarios (NOT targets; EPS × multiple).

• BEAR (~$110–180): budget air-pocket / CR / munitions de-escalation + a fixed-price EAC charge resurfaces + an EPS-quality de-rate. Clean core EPS holds ~$7 but the multiple compresses to ~16x as the market stops paying a growth multiple for sub-WACC ROIC → ~$112; or a GAAP ~$10 (guidance miss / failed H2 ramp) at ~18x → ~$180.
• BASE (~$210–265): guide roughly delivered; GAAP EPS ~$11.5 at ~22–24x (modest de-rate) → ~$255–265; equivalently normalized core ~$8.5 at ~25x → ~$212. The SOTP (~$288–307) sits at/above the top of this band — which is why the stock is ~$295.
• BULL (~$325–365): 2028 framework delivered (~$13–14 GAAP EPS), the munitions supercycle persists, Axyv crystallizes a rich MSL mark funding buybacks, and consolidated ROIC grinds toward WACC. $13 × 25x → ~$325; $14 × 26x + an Axyv re-rate → ~$364.

Spot ~$295 sits above the base midpoint and below the bull — the market is already pricing a successful-base-to-mild-bull outcome.

What the market is underwriting — correctly: the genuine organic acceleration, strong FCF, the CSD premium, and a conservative ~3.6% implied terminal growth. Too generously: a prime-premium EV/EBITDA for the lowest-ROIC prime (treating the sub-WACC return as a curable artifact); a GAAP-EPS guide flattered by pension/monetization/tax/reporting; an Axyv unlock the SOTP shows is modest; and the cyclicality of the fastest-growing drivers at what may be a budget-cycle peak.

§10 Verdict: fully-to-richly valued, no margin of safety, modest optionality. On the GAAP guide LHX looks “only” ~25.6x; on clean earnings it is ~30–38x — a growth multiple stapled to the lowest ROIC in the prime group, at a premium EV/EBITDA to higher-quality peers. SOTP confirms no break-up floor. The reverse-DCF (~3.6% implied) is the one comfort — expectations are not heroic — but the price embeds successful execution of a back-half-weighted, partly-manufactured EPS ramp through a budget-cycle peak. Fair value, not a bargain.

11. Variant Perception

Consensus. Bullish-to-constructive: a “premium mid-cap defense compounder” riding a generational supercycle, a credible self-help margin story (LHX NeXt), the “Trusted Disruptor” positioning, and a near-term Axyv/SOTP catalyst — with the 25.6x GAAP-guide P/E and ~5.4% FCF yield quoted as “reasonable for the growth.” Consensus treats the sub-WACC ROIC as a temporary goodwill artifact that organic growth and amort roll-off will cure.

Strongest bull case. (1) Growth is real, organic, and funded — +15% Q1-26 vs GD/LMT low-single-digit, backlog 1.9x heading to $60–70B, international book-to-bill 2.2x; the highest defense-growth beta in the group. (2) CSD is a genuine scale+captivity moat earning ~24% margins, arguably under-credited inside the consolidated number. (3) LHX NeXt is a controllable internal margin lever independent of the budget. (4) Axyv + SOTP could crystallize a richer MSL mark and fund buybacks; the $1B DoW preferred validates strategic value. (5) Tangible-capital ROIC is ~18–25% — the operating business is high-quality; the low consolidated ROIC is purely goodwill that organic growth will dilute over time. (6) The factor tape (beta 0.40, +0.10 alpha, dividend/gold tilt, anti-Growth) says this is a defensive, low-beta quality name, not a crowded momentum trade, and at ~22% off the ATH not a falling knife — room to re-rate on the supercycle option.

Strongest bear case. (1) Sub-WACC ROIC (~5.9% vs ~8% WACC): the enterprise destroys returns on capital; the $26.5B premium transferred value to sellers, and “cure via amortization” is slow and uncertain. (2) Poor EPS quality: ~$1.40 pension, ~$0.45 finite monetization, erratic-low tax; the 2026 GAAP guide is flattered by a reporting switch + amort roll-off + back-half weighting; clean EPS is ~$6.50–7.00, so the stock is really ~30–38x. (3) Full-price M&A near cycle highs; the 2026 un-conglomeration (SPPS sale at an impairment, Axyv ~3 years after buying Aerojet) is a tacit admission the roll-up under-delivered. (4) Budget/cyclical peak: FY27 is a request; the strongest drivers sit where the capital cycle is active (government-funded over-supply); Jun-18’s −6.4% on de-escalation is a live preview. (5) 75% fixed-price (highest in group) — LMT’s ~$3.6B charges show the risk. (6) Zero open-market insider buys across 60 months, including the 2023 ~$161 low, plus a Kubasik 83,000-share discretionary sale at $279.90 near the high. (7) Premium valuation vs higher-ROIC peers; SOTP = no floor.

The 3–5 assumptions that matter most (and falsification).

• A. The organic acceleration is durable, not a budget-cycle peak. Falsify bull: two quarters of decelerating organic growth / book-to-bill <1.0 / FY27 cut below request. Falsify bear: MAC books and organic stays high-single/double-digit into 2027.
• B. Segment margins reach/hold ~16% (LHX NeXt sustainable). Falsify bull: a >$100M fixed-price reach-forward charge or margin stalls <15%. Falsify bear: clean ~16%+ for 2–3 quarters ex one-time gains.
• C. Sub-WACC ROIC is a curable goodwill artifact. Falsify bull: ROIC stuck ~6% in 2027–28 despite growth. Falsify bear: ROIC grinds toward 8–9% as amort rolls off and organic NOPAT compounds.
• D. EPS quality normalizes. Falsify bull: pension income swings negative on rates; monetization gains fade and core EPS is exposed as ~$7. Falsify bear: the GAAP ramp is delivered on clean operating drivers.
• E. Axyv/SOTP unlocks value. Falsify bull: Axyv prices at/below the embedded mark, or stranded costs eat the uplift. Falsify bear: Axyv IPOs >$15B EV and funds accretive buybacks.

Factor-positioning read on where consensus is offsides. The factor tape says LHX is a defensive, low-beta, positive-alpha dividend/quality name with a gold/oil geopolitical-hedge tilt and an anti-Growth loading — it trades like a defensive supercycle beneficiary, not a momentum darling (contrast HWM/RTX at 85th-percentile own-history valuations). Its closest twin is NOC (0.889), and at ~22% off the ATH with rs_6m only +5.0 it is neither a crowded long nor a falling knife. The leaderboard shows a strong recent run (y1 +20.4%, Sharpe 0.74; y3 +17.9%/yr) but a high lifetime max drawdown (−57%) and a sharply negative latest quarter (m3 ~−16% actual) — a cyclical that ran hot and rolled over, not a steady low-drawdown compounder. Where consensus may be offsides: the bear variant is the under-appreciated one. The market’s defensive framing and modest implied terminal growth lull holders into treating the sub-WACC ROIC and flattered EPS quality as non-issues; the gold/oil tilt that powered the 2025–26 supercycle bid cuts both ways — de-escalation is a headwind, as Jun-18 showed. If the budget/munitions cycle rolls, this “defensive” name re-rates toward its pure-prime EV/EBITDA peers (~13–16x) precisely because it has the worst ROIC. The consensus error is quality-of-earnings and returns-on-capital complacency, not growth skepticism.

§11 Verdict. Consensus is right on growth and FCF, complacent on ROIC and EPS quality. The strongest non-consensus insight is that the headline 25.6x masks a ~30–38x clean multiple on the lowest-ROIC prime, and the factor tape’s “defensive” framing under-prices cyclical/budget downside. Finely balanced: the bull needs the supercycle to persist and ROIC to cure and Axyv to unlock — three things, each plausible, none proven.

12. Fact vs. Interpretation Table

13. Open Questions

1. Will consolidated ROIC visibly converge toward WACC (~8%) by 2027–28 as acquired intangibles amortize and organic NOPAT compounds — or stay stuck ~6%, proving the franchise cannot out-earn the price paid? This is the crux.
2. What are the audited Axyv standalone financials and leverage (the S-1 is confidential)? At what EV does it IPO, and does LHX use proceeds to delever / buy back stock?
3. Are the Feb-2026 Investor-Day 2028 framework targets (revenue/margin/EPS/FCF) as circulated accurate, and how much depends on MAC orders converting to backlog?
4. How clean is the FY26 GAAP EPS ramp — how much of the H2 weighting is operating vs. pension, monetization gains, and tax timing?
5. Does the FY27 ~$1.5T request get appropriated, and on what timeline (CR risk)?
6. What is the exact consecutive-dividend-increase streak (left unverified from the proxy; confirm against IR)?
7. Will the CFO transition (Sharp) and segment-leader churn introduce guidance/accounting-philosophy shifts during the most complex restructuring in company history?

14. What Must Be True

Bull case — what must be true:

• The organic acceleration is durable: backlog converts to $60–70B (MAC books) and organic growth stays high-single/double-digit into 2027.
• Segment margins reach and hold ~16%+ on clean operating drivers (LHX NeXt sustained), with no large fixed-price reach-forward charge.
• Consolidated ROIC grinds toward ~8–9% as intangibles roll off and organic growth out-earns the acquisition base.
• Axyv IPOs at a rich mark (>$15B EV) and proceeds fund accretive buybacks/deleveraging.
• Falsification test: two consecutive quarters of decelerating organic growth or book-to-bill <1.0, OR consolidated ROIC stuck ~6% in 2027–28 despite the growth, OR a fixed-price EAC charge >$100M.

Bear case — what must be true:

• The budget/munitions cycle rolls (FY27 cut below request, or de-escalation cools munitions demand), exposing the cyclicality of the fastest-growing leg.
• The flattered EPS base (pension/monetization/tax) is exposed as clean ~$7, and the market re-rates the lowest-ROIC prime toward pure-prime EV/EBITDA (~13–16x).
• A fixed-price reach-forward charge demonstrates the 75%-FP execution risk.
• Falsification test: clean segment margins print 16%+ for 2–3 quarters ex one-time gains, the GAAP EPS ramp is delivered on operating drivers, ROIC trends toward WACC, AND organic growth stays double-digit — i.e., the franchise out-earns the price paid and the quality concerns prove unfounded.

15. Source Appendix

Primary filings (SEC EDGAR):

• L3Harris Technologies FY2025 Form 10-K (fiscal year ended Jan-2-2026), filed 2026-02-12 — Item 1 Business, Item 1A Risk Factors, Item 7 MD&A, Notes 6/7/13/14/16.
• L3Harris Q1-2026 Form 10-Q, filed 2026-04-30 — Note O Business Segments, Note M Backlog, MD&A budget environment, segment results.
• L3Harris 2026 DEF 14A (proxy), filed 2026-04-01 — executive compensation, incentive metrics.
• Form 8-K material events 2024–2026 (segment realignment Jan-5-2026; CFO/leadership changes Mar-2026; earnings releases); Form 4 insider-transaction corpus (297 filings since 2021-06).

Earnings calls: Q4-2025 (2026-01-29) and Q1-2026 (2026-04-30) transcripts read in full; framework/guidance/Axyv terms sourced therein. Investor-Day “2028 framework” referenced as company IR material (Feb-25-2026), not a filing.

Quantitative data: company filings and standard market-data sources (income statement, balance sheet, cash flow, profitability/valuation ratios, enterprise value, per-share data; 5-year price history; own-history valuation percentiles; published factor-model loadings and risk-adjusted return statistics).

Peer comparables (public filings): Northrop Grumman (NOC), Lockheed Martin (LMT), General Dynamics (GD), RTX, Howmet (HWM), TransDigm (TDG) — used for industry framing and comp-set placement.

Frameworks: Greenwald & Kahn, Competition Demystified (barriers to entry, moat taxonomy, EPV vs. asset value); Marathon/Chancellor, Capital Returns (capital-cycle and asset-growth analysis).

Note: third-party market data was reconciled to the underlying SEC filing, which governs where they disagree. Management commentary is treated as hypothesis, validated against filings and external evidence.

APPENDIX A — Standard Diligence Questionnaire

L3Harris Technologies, Inc. (NYSE: LHX) · June 19, 2026

Supplemental to the analysis. Answers are grounded in the filings; Fact/Interpretation/Assumption labels are applied where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions cluster around: (1) Is the sub-WACC ROIC curable? — i.e., will organic growth and intangible-amortization roll-off lift consolidated ROIC from ~6% toward cost of capital, or did the L3/Aerojet deals permanently impair returns? (2) How clean is the EPS? — how much of the FY26 GAAP EPS jump to $11.50 is operating vs. pension income, monetization gains, tax, and the reporting-basis change? (3) What does Axyv unlock? — is the Missile Solutions IPO a genuine SOTP value-creation event or financial engineering at the cyclical peak? (4) Is the growth durable or budget-peak cyclical? — does the $25B MAC pipeline convert, and what happens to munitions demand on de-escalation? (5) Is the premium-to-peers multiple deserved given LHX has the lowest ROIC in the prime group? These are the right questions, and the memo argues the bear answers are under-appreciated.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Closer to a cyclical high than a low. Revenue, margins, and orders are all riding the strongest defense-demand setup in a generation (Interpretation). The risk is that the fastest-growing leg (munitions/SRM) is replenishment-cyclical and sits where the government is deliberately funding over-supply.

Driven by the external environment or internal actions? Both. External: the budget supercycle (US $859B FY26, ~$1.5T FY27 request, NATO 5%, Golden Dome, Iran). Internal: the LHX NeXt cost program (segment margin to ~16%) and the organic order inflection. The margin story is more internal; the revenue story is more external.

How stable are revenues? Highly visible near-term (backlog ~$40.7B = 1.9x revenue; ~40% converts within 12 months) but ultimately budget-appropriation-dependent and subject to CR/shutdown timing.

Outlook for products/services? How big is the market? Large and growing through the cycle: a ~$1.5T US national-defense topline request, NATO rearmament, and multi-decade modernization roadmaps (10-year tactical-radio cycles ~20% complete internationally). International is the standout (book-to-bill 2.2x). Domestic and international, with ~22% of revenue already international.

Business Quality & Competitive Moat

More or less competitive industry? Structurally protected (clearances, ITAR, past-performance barriers) but facing procurement reform (OTAs) that explicitly aims to lower entry barriers for non-traditional entrants — a slow-moving competitive risk, especially for the merchant/subcontractor mix LHX carries.

How profitable is the business (ROIC, ROE)? The tension of the whole report. Segment operating margins are competitive (~15.4% blended, CSD ~25%); but consolidated ROIC is only ~5.9% (sub-WACC) because of $26.5B of acquired goodwill/intangibles. Reported ROE (~38%) is a meaningless leverage/thin-equity artifact. Ex-goodwill ROIC ~18%, cash ROIC ex-goodwill ~25% — the operating business is good; the price paid for it is the problem.

How profitable is the industry — competitors, barriers? A high-barrier oligopoly serving a monopsony that caps prime margins ~10–11% / low-teens ROIC. Few competitors; extraordinary barriers; capped rents.

Can the business be easily understood? Reasonably — three segments grouped by business model. The complexity is in the adjustments (pension, monetization gains, intangible amort, EAC, the 2026 reporting switch), which obscure clean earnings.

Undermined by foreign low-cost labor? No — cleared US workforce, ITAR-controlled, classified work; the moat is the opposite of labor-arbitrageable.

Do brands matter? Not consumer brands, but “Harris” tactical radios and past-performance reputation function as a procurement brand / qualification asset.

Nature of competition; switching costs? Program-by-program competition with multi-decade lock-in once won. Switching costs are highest in CSD (radio interoperability, recertification, combat-criticality), real but thinner in SMS (incumbency), and present-but-merchant in MSL (motor qualification).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The franchise value of the CSD installed base and the SRM scarcity position are not separately carried at economic value; conversely, much of the balance sheet is recognized intangibles/goodwill that may be impaired (an $85M SPPS impairment was taken in FY25).

Off-balance-sheet liabilities? Standard for a prime: operating leases, pension/OPEB obligations (with the offsetting non-service income that flatters EPS), and contract/legal contingencies. Nothing unusual flagged.

How conservative is the accounting? Mixed. Percentage-of-completion (cost-to-cost) requires EAC estimates that have swung materially (−$85M FY23 to +$47M FY25). The recurring “legacy-asset monetization” credit and the reliance on non-service pension income are quality-of-earnings concerns; the 2026 move to GAAP segment/EPS reporting is a transparency improvement.

How CapEx-hungry? Capital-light (~2–2.5% of sales; ~$0.4–0.6B), supporting ~190% FCF/NI conversion — though capex is guided up ~35–40% in FY26 for SRM capacity.

Capital Allocation & Management

How much FCF, and how is it used? ~$3.0B/year. Priorities: deleveraging (net debt $13.4B → $11.1B), a growing dividend (~$0.9B, ~56% payout), and buybacks (~$1.15B FY25; shares 214M → 187M). Philosophy is balanced and shareholder-aware on cash flow — the weakness is in the big strategic-capital (M&A) decisions.

Significant acquisitions recently? The 2023 Aerojet deal ($4.7B all-cash) and, before that, the 2019 L3 merger — both full-priced near cycle highs (Interpretation). The 2026 direction has reversed to divestiture/IPO (SPPS 60% sale, Axyv).

Buying back shares? Yes, at acceptable-to-good prices; shares down ~12.6% over five years.

Issuing large amounts of stock to insiders? Routine equity comp (grants/options); the issue is the absence of open-market buying, not excessive issuance.

Compensation policy? Above-average design: annual on FCF/EBIT/Revenue/Segment-margin; long-term PSUs on 33% EPS / 33% ROIC / 33% relative TSR. Revenue in the annual plan is the one mild empire flag. CEO Kubasik FY25 total comp $25.6M (+23%); combined Chairman+CEO role is a governance concern.

Motivations of management? Incentives are reasonably value-aligned (ROIC + relative TSR), but the total absence of open-market purchases — even at the 2023 low — and a large CEO discretionary sale near the 2025 high suggest management monetizes the stock rather than accumulating it.

Valuation & Market Data

ADR, MLP, or K-1? No — a US-domiciled C-corp, common stock, NYSE-listed; standard 1099 treatment.

Dividend policy? ~$0.9B/year, ~56% payout, ~1.7% yield; a long-standing annual grower (legacy Harris 20+ years; exact combined streak unverified).

How profitable? See above — competitive segment margins, sub-WACC consolidated ROIC, strong FCF conversion.

Net income diverging from cash from operations? Yes — FCF/NI ~190%, because D&A (incl. $769M non-cash intangible amort) and pension net to large add-backs. The divergence is favorable for cash but partly reflects the non-cash “return of” the M&A premium, so strong cash conversion and weak economic-earnings quality coexist.

Risks & Downside

What would cause the stock to decline? A budget air-pocket/CR; a fixed-price EAC reach-forward charge; a failed back-half-weighted EPS ramp; a valuation de-rate toward peer EV/EBITDA; pension reversal; munitions de-escalation; Axyv pricing below the embedded mark.

Catastrophic-loss risk? Very low — investment-grade balance sheet, 2x backlog, diversified programs, a monopsony customer that does not default.

Total-loss risk? Negligible.

Recent News & Events

Has the environment changed recently? Yes — materially favorable near-term: GFY2026 appropriations $859B (Feb-2026), the ~$1.5T FY27 request, NATO 5%, the Jun-2026 Iran escalation and Defense Production Act invocation. Offset by the request-stage nature of FY27 and the Jun-18 de-escalation sell-off.

Significant acquisitions/divestitures? The pivot to un-conglomeration: the 60% SPPS sale to AE Industrial Partners, the $1B DoW preferred into MSL, and the confidential Axyv (Missile Solutions) IPO S-1.

Change in accounting policies? Yes — the move to GAAP segment operating income and GAAP EPS reporting effective fiscal 2026 (a transparency improvement, but it complicates year-over-year EPS comparison).

Recent changes — markets, facilities, management? Segment realignment (4 → 3); CFO change (Bedingfield → Sharp) plus segment-leader churn; >$0.5B of capacity investment at Aerojet; LHX NeXt completed a year early.

APPENDIX B — Source Appendix

L3Harris Technologies, Inc. (NYSE: LHX) · June 19, 2026

All material quantitative figures were reconciled to primary SEC filings, which govern where third-party aggregators disagree. Management commentary was treated as hypothesis and validated against filings and external evidence.

Primary Sources — SEC Filings (EDGAR)

Primary Sources — Earnings Calls

Management’s Feb-25-2026 Investor-Day “2028 financial framework” targets are company investor-relations material, not SEC filings; they are treated as management guidance/interpretation, not audited fact.

Quantitative Data Sources (reconciled to filings)

• Market-data provider — multi-year income statement, balance sheet, cash-flow statement; profitability ratios (ROIC, ROE, margins, tax rate, payout); enterprise value; valuation multiples; per-share data. Used for trend analysis and the ROIC computation, cross-checked to the 10-K.
• Price-data provider — 5-year daily price/OHLCV (price arc, EMAs, beta/alpha); valuation_index own-history valuation percentiles (P/E, P/B, P/S vs. the stock’s own multi-year range); news feed (Iran conflict, Axyv IPO underwriters, VAMPIRE order, DPA).
• Factor-model provider — factor loadings (Momentum/Value/Quality/LowVol/Size/Growth/Market + sector/industry/macro), leaderboard (risk-adjusted horizon returns, Sharpe, max drawdown), stock-info (beta, alpha, relative strength), related-stocks (factor-similar peers), specific (idiosyncratic) volatility.

Peer Comparables (public filings)

Northrop Grumman (NOC), Lockheed Martin (LMT), General Dynamics (GD), RTX, Howmet (HWM), TransDigm (TDG) — used for industry-structure framing and comp-set placement (EV/EBITDA, P/E, FCF yield, ROIC, own-history percentile).

Analytical Frameworks

• Bruce Greenwald & Judd Kahn, Competition Demystified — barriers to entry, moat taxonomy (supply/cost, demand/captivity, economies of scale + captivity), market-share-stability and ROIC tests, EPV vs. asset value.
• Edward Chancellor (ed.), Capital Returns (Marathon Asset Management) — supply-side capital-cycle analysis, the asset-growth anomaly, and the tendency of high returns / scale acquisitions to mean-revert.

Key Reconciliation Notes

• EPS: FY25 GAAP diluted EPS $8.52 (10-K). “Clean core operating EPS” of ~$6.50–7.00 is an analyst normalization stripping ~$1.40 non-service pension income, ~$0.45 finite legacy-asset-monetization gains, and normalizing an erratic-low tax rate.
• Book value: Reported BVPS ($104.55) is correct (equity $19.6B / ~187M shares); one aggregator’s per-share book figure was mismapped and was discarded. Tangible book is negative (~−$6.9B); P/TBV is not meaningful.
• Enterprise value: ROIC’s FY25 snapshot EV (~$65.1B) was usable because the FY-end close (~$293.57) is within ~0.4% of the reference price ($294.82); net debt ~$10.05B.
• Intangible amortization: ~$769M in FY25 (the broader ~$1.2B “D&A” figure includes ~$453M of depreciation).